

**DINSMORE
& SHOHL LLP****FACSIMILE TRANSMITTAL**
February 26, 2003*from* **HOLLY D. KOZLOWSKI**
Direct: 513-977-8568 / Fax: 513-977-8141 / holly.kozlowski@dinslaw.com

To: Examiner A. Pulliam
Firm: USPTO, GAU 1615
Fax Number: 1-703-305-3592
Client Number: 10914-11
Pages: 15
(including cover)
Comments:

FAX RECEIVED
FEB 27 2003
GROUP 1600

OFFICIAL

If there are any problems in receiving this transmission, please call the fax room at (513) 977-8483 immediately. Thank you.

Notice

This message is intended only for the use of the individuals or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this notice is not the intended recipient or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this notice in error, please notify us immediately by telephone and return these papers to us at the address below via first class mail.

Cincinnati • 1900 Chemed Center • 255 East Fifth Street • Cincinnati, OH 45202 • Phone: (513) 977-8200

26/7C
PATENT

Docket No. 10914-11

CERTIFICATE OF FACSIMILE

I hereby certify that this paper is being transmitted via facsimile
to Group Art Unit 1615; Box AF; Commissioner of Patents,
Washington, DC 20231 at facsimile number 703/305-3592
on February 26, 2003.

Bel
3-4-03**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant: Isa Odidi et al : Paper No.:
Serial No. : 09/403,437 : Group Art Unit: 1615
Filed: October 21, 1999 : Examiner: A. Pulliam
For: **Controlled Release Formulations Using Intelligent Polymers**

AMENDMENT UNDER 37 CFR 1.116

Box AF
Commissioner for Patents
Washington, DC 20231

Dear Sir:

In response to the Official Action dated November 18, 2002 and the Advisory Action dated February 10, 2003, please amend the present application as follows:

In the Claims:

Please cancel claim 4.

Please amend claims 1, 14, 25, 30, 33 and 34 to read as follows:

1. (Fifth Amendment) A controlled release pharmaceutical composition comprising:
- (a) at least one pharmaceutically active substance having a water contact angle
 - (b) such that $\cos \theta$ is between +0.9848 and -0.9848;
 - (b) a first intelligent polymer component; and
 - (c) a second intelligent polymer component having opposite wettability characteristics to said first intelligent polymer component, said second intelligent polymer